Tirabrutinib

Name: Tirabrutinib in Primary central nervous system lymphoma: Pathophysiology
Published: 2026-09-14T15:39:06-04:00

Primary central nervous system lymphoma

Manufacturer: Deciphera Pharmaceuticals
Regulatory submission: NDA submitted December 2025
Launch: Anticipated in the fiscal year ending March 2027
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description

Pathophysiology

2 evidence topics · 2 sources

B-cell histology

“more than 95% of PCNSL cases are diffuse large B cell lymphoma (DLBCL)” (opens the source at this quote in a new tab)

Immunosuppression and viral association

“Immunosuppression-related primary CNS lymphomas are almost always associated with the Epstein-Barr virus.” (opens the source at this quote in a new tab)